Kevin Tan - 09 Jan 2026 Form 4 Insider Report for Solid Biosciences Inc. (SLDB)

Role
CFO & Treasurer
Signature
/s/ Kimberly Cornwell as attorney-in-fact for Kevin Tan
Issuer symbol
SLDB
Transactions as of
09 Jan 2026
Net transactions value
-$30,060
Form type
4
Filing time
13 Jan 2026, 17:02:31 UTC
Previous filing
18 Aug 2025
Next filing
02 Feb 2026
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Tan Kevin CFO & Treasurer C/O SOLID BIOSCIENCES INC., 500 RUTHERFORD AVENUE, THIRD FLOOR, CHARLESTOWN /s/ Kimberly Cornwell as attorney-in-fact for Kevin Tan 13 Jan 2026 0001884056

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction SLDB Common Stock Options Exercise +11,250 +28% 51,804 09 Jan 2026 Direct F1, F2
transaction SLDB Common Stock Sale $30,060 -5,704 -11% $5.27 46,100 13 Jan 2026 Direct F2, F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction SLDB Restricted Stock Units Options Exercise $0 -11,250 -50% $0.000000 11,250 09 Jan 2026 Common Stock 11,250 Direct F1, F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 Restricted stock units convert to common stock on a one-for-one basis.
F2 Includes 4,152 and 4,152 shares of common stock acquired under the Solid Biosciences Inc. Employee Stock Purchase Plan on May 30, 2025 and November 28, 2025, respectively.
F3 This sale was made to cover withholding taxes following the vesting of previously granted RSUs pursuant to a durable automatic sale instruction letter adopted by Mr. Tan on August 15, 2024 effecting the sell-to-cover election. The sale does not represent a discretionary trade by Mr. Tan.
F4 The restricted stock units were granted on January 9, 2023 (the "Grant Date") and vest over four years, with 25% of the original number of shares vesting on each anniversary of the Grant Date until the fourth such anniversary.